Weekly Mass Torts Bulletin 2023-June-5
Opvee, the first nalmefene hydrochloride nasal spray, was given the go-ahead by the U.S. Food and Drug Administration for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older.